"...agree, why isnt todays ann about tasly generating more enthusiasm"
I suspect that it is not evident in this announcement was Tasly has done that is so significant.
"...leveraging ...expertise and knowledge base in order to map out (a) pathway,..." reads to me a lot like mere management speak which can be translated into:
"We are going to keep meeting and talking to people and see what we can do to move this thing forward."
Which is nothing at all unexpected.
I mean, its not as if they have paid MSB any sum of money or committed any more capital to funding anything.
So, to answer your question, I'm guessing that the market's apparent indifferent attitude is because the market might be interpreting this announcement as Tasly saying, "Yeah, we'll agree to allocate some of our internal human resources to promoting this story, but at this stage we're not parting with any more capital going MSB's way."
But what MSB needs is capital, not more promotion of its story.
(For promotion of the MSB story has occurred in spades over the years. Unfortunately, at some stage clear and unambiguous signs of commercialisation to a point approaching self-sustainability need to become manifest, or else the market becomes increasingly immune to yet more "promotion".)
- Forums
- ASX - By Stock
- MSB
- Mesoblast - takeover target?
Mesoblast - takeover target?, page-78
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.16 |
Change
-0.030(2.52%) |
Mkt cap ! $1.324B |
Open | High | Low | Value | Volume |
$1.18 | $1.22 | $1.15 | $5.400M | 4.591M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
30 | 54902 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.17 | 34820 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
62 | 207321 | 1.155 |
18 | 233778 | 1.150 |
13 | 204738 | 1.145 |
11 | 204366 | 1.140 |
3 | 23475 | 1.135 |
Price($) | Vol. | No. |
---|---|---|
1.165 | 66541 | 12 |
1.170 | 91219 | 13 |
1.175 | 60091 | 8 |
1.180 | 74516 | 7 |
1.185 | 28927 | 2 |
Last trade - 15.31pm 15/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online